GHRS - GH Research: Steady Expenses And $229M Cash Position For 2026 Runway | Benzinga
The clinical-stage psychedelics biotech GH Research PLC (NASDAQ: GHRS) reported its financial results for Q3 2023 ended September 30, showing:
-
Cash, cash equivalents and other financial assets and marketable securities totaled $228.7 million by Sept. 30, compared to $251.7 million by Dec. 31, 2022..
-
Cash and cash equivalents for the Europe-based company were $86.5 million by Sept. 30, an almost 11% QoQ decrease from the $96.9 held by June 30 and nearly a 50% cut compared to the $166 million held by Dec. 31, 2022.
See full Q2 results.
-
Three and nine-month R&D expenses of $7.1 million and $21.6 million, compared to $4.6 million and $13.6 million during the comparable quarters in 2022.
-
Three and nine months G&A expenses of $2.6 million and $8.5 million, compared to $2.0 million and $7.8 million in the same quarters in 2022.
-
Quarterly net loss of $5.6 million (or $0.11 per share) vs. $0.4 million (or $0.01 per share) during the same quarter in 2022.
-
Accumulated deficit of $56.7 million by Sept. 30, an over 10% QoQ increase and an almost 75% nine-month ...